Unlocking the Potential of UBE2I as a Drug Target or Biomarker

Target Name: UBE2I

NCBI ID: G7329

UBE2I

Unlocking the Potential of UBE2I as a Drug Target or Biomarker

Introduction

Unlock the Potential of UBE2I

The UBE2I (uracil dimeric nucleotide diphosphatase) gene is located on chromosome 18q21 and encodes a protein known as UBE2I (uracil dimeric nucleotide diphosphatase). This gene has been implicated in a wide range of cellular processes, including DNA replication, repair, and metabolism. UBE2I is a key enzyme in the DNA damage response (DDR), a critical process that helps cells respond to DNA damage and ensure the integrity of genetic information.

The DDR is a complex process that involves multiple proteins, including UBE2I, working together to repair damaged DNA. UBE2I plays a crucial role in the initiation of the DDR response by catalyzing the conversion of pyrimidine-ribose (PR) to pyrimidine- dihydroorotate (PDH) during the G1 phase of the cell cycle. PDH is a key intermediate step in the DDR repair process, and UBE2I's activity in this process has been implicated in the development of various diseases, including cancer.

Drug Targeting UBE2I

Given its importance in the DDR and its potential involvement in various diseases, UBE2I has become an attractive drug target for researchers. Several studies have investigated the effects of drugs on UBE2I's activity and have identified potential drug targets for this protein.

One of the most promising drug targets for UBE2I is the inhibition of its activity, which could lead to the collapse of the DDR response and enhance the risk of DNA damage. Several studies have shown that inhibitors of UBE2I, such as inhibitors of the phosphorylation reaction or inhibitors of the ATP-binding site, can significantly reduce the activity of this enzyme.

Biomarker Identification

UBE2I is also a potential biomarker for several diseases, including cancer. The DDR is a critical pathway for cancer development, and UBE2I's activity in this pathway could be used as a biomarker to monitor the effectiveness of anti-cancer drugs. Several studies have shown that the expression of UBE2I is significantly increased in various types of cancer, including breast, lung, and colorectal cancer.

Functional Analysis of UBE2I

Recent studies have provided new insights into the functional organization of UBE2I within the DDR complex. These studies have shown that UBE2I is part of the DDRC1 complex, which is responsible for initiating the DDR response. UBE2I's activity in this complex is critical for the initiation of the DDR response, as its catalytic activity is required for the conversion of PR to PDH.

Conclusion

In conclusion, UBE2I is a protein that plays a crucial role in the DDR response and is involved in a wide range of cellular processes, including DNA replication, repair, and metabolism. Its activity in the DDR is critical for the development and progression of various diseases, including cancer. The inhibition of UBE2I's activity is an attractive drug target for researchers, and its expression is also a potential biomarker for cancer. Further research is needed to fully understand the functional organization of UBE2I within the DDR complex and its potential as a drug target and biomarker.

Protein Name: Ubiquitin Conjugating Enzyme E2 I

Functions: Accepts the ubiquitin-like proteins SUMO1, SUMO2, SUMO3, SUMO4 and SUMO1P1/SUMO5 from the UBLE1A-UBLE1B E1 complex and catalyzes their covalent attachment to other proteins with the help of an E3 ligase such as RANBP2, CBX4 and ZNF451. Can catalyze the formation of poly-SUMO chains. Necessary for sumoylation of FOXL2 and KAT5. Essential for nuclear architecture and chromosome segregation. Sumoylates p53/TP53 at 'Lys-386'. Mediates sumoylation of ERCC6 which is essential for its transcription-coupled nucleotide excision repair activity (PubMed:26620705)

The "UBE2I Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about UBE2I comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets